IVUSE+ uses an async telehealth model: complete a health assessment online, and a licensed provider reviews your history, medications, and goals to determine eligibility
Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats
Manufactured in a facility that produces products containing milk, eggs, fish, shellfish, tree nuts, wheat, and soy.
Immediate consultation is warranted if you develop: Rapid weight gain accompanied by swelling, shortness of breath, or decreased urine output (possible fluid retention or heart failure) Return of obesity-related complications such as uncontrolled blood pressure, worsening diabetes control (elevated blood glucose readings), or sleep apnea symptoms Severe increase in appetite that interferes with daily functioning or leads to binge eating episodes Psychological distress, depression, or anxiety related to weight changes Severe abdominal pain, especially radiating to the back, with or without vomiting (possible pancreatitis) Right upper quadrant abdominal pain, fever, or yellowing of skin/eyes (possible gallbladder disease) Gastrointestinal symptoms that persist after stopping Zepbound Follow-up schedule should be tailored to your individual risk factors and comorbidities
At 12 months, the WW group lost an average of 4.4 kg, compared to 1.7 kg in the DIY group